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BACKGROUND
The benefit of an implantable cardioverter–defibrillator (ICD) in patients with 
symptomatic systolic heart failure caused by coronary artery disease has been well 
documented. However, the evidence for a benefit of prophylactic ICDs in patients 
with systolic heart failure that is not due to coronary artery disease has been based 
primarily on subgroup analyses. The management of heart failure has improved 
since the landmark ICD trials, and many patients now receive cardiac resynchroni-
zation therapy (CRT).
METHODS
In a randomized, controlled trial, 556 patients with symptomatic systolic heart failure 
(left ventricular ejection fraction, ≤35%) not caused by coronary artery disease were 
assigned to receive an ICD, and 560 patients were assigned to receive usual clinical care 
(control group). In both groups, 58% of the patients received CRT. The primary out-
come of the trial was death from any cause. The secondary outcomes were sudden 
cardiac death and cardiovascular death.
RESULTS
After a median follow-up period of 67.6 months, the primary outcome had occurred in 
120 patients (21.6%) in the ICD group and in 131 patients (23.4%) in the control group 
(hazard ratio, 0.87; 95% confidence interval [CI], 0.68 to 1.12; P = 0.28). Sudden car-
diac death occurred in 24 patients (4.3%) in the ICD group and in 46 patients (8.2%) 
in the control group (hazard ratio, 0.50; 95% CI, 0.31 to 0.82; P = 0.005). Device infec-
tion occurred in 27 patients (4.9%) in the ICD group and in 20 patients (3.6%) in the 
control group (P = 0.29).
CONCLUSIONS
In this trial, prophylactic ICD implantation in patients with symptomatic systolic heart 
failure not caused by coronary artery disease was not associated with a significantly 
lower long-term rate of death from any cause than was usual clinical care. (Funded by 
Medtronic and others; DANISH ClinicalTrials.gov number, NCT00542945.)
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In both European and U.S. guidelines, prophylactic implantation of an implantable cardioverter–defibrillator (ICD) is a class 1 
recommendation for patients with heart failure 
and reduced left ventricular systolic function.1,2 
However, the evidence for a benefit is much 
stronger for patients with ischemic heart disease 
than it is for patients with heart failure from 
other causes. Over the past two decades, ICD 
implantation has been shown to be associated 
with substantial reductions in the rate of sudden 
cardiac death and total mortality in patients 
with ischemic heart disease.3-6 In the case of 
patients without ischemic heart disease, one trial 
showed an association between ICD implanta-
tion and a reduction in the rate of death attrib-
uted to arrhythmias, but no single trial has 
shown a convincing effect on total mortality.7-9 
The Comparison of Medical Therapy, Pacing, and 
Defibrillation in Heart Failure (COMPANION) 
study, which randomly assigned 1520 patients 
with New York Heart Association (NYHA) class 
III or IV heart failure to receive medical therapy, 
a cardiac resynchronization therapy (CRT) pace-
maker, or a CRT defibrillator, showed signifi-
cantly lower all-cause mortality in association 
with a CRT defibrillator than with medical treat-
ment alone, but a CRT defibrillator was not 
shown to be superior to a CRT pacemaker.10 The 
only randomized trial involving patients with 
nonischemic systolic heart failure in which a 
significant benefit with regard to all-cause mor-
tality has been reported in association with the 
implantation of an ICD is the Sudden Cardiac 
Death in Heart Failure Trial (SCD-HeFT), which 
included 2521 patients, half of whom had non-
ischemic systolic heart failure.6 However, the 
positive effect of ICD treatment was confined to 
patients in NYHA class II, and no patients re-
ceived concomitant CRT. In addition, medical 
treatment for heart failure has changed since 
SCD-HeFT was conducted.
Given the limited evidence of a benefit from 
the implantation of an ICD in patients with 
chronic nonischemic heart failure, we conducted 
a randomized trial in which patients whose con-
dition was stable and who had chronic symp-
tomatic heart failure, reduced ejection fraction, 
and increased levels of natriuretic peptide with 
or without a need for CRT were randomly as-
signed either to receive or not to receive an ICD.
Me thods
Trial Oversight
The Danish Study to Assess the Efficacy of ICDs 
in Patients with Non-ischemic Systolic Heart Fail-
ure on Mortality (DANISH) was an investigator-
initiated multicenter, randomized, unblinded, 
controlled trial that was conducted at all centers 
in Denmark at which ICDs were implanted. The 
trial design and baseline characteristics of the 
patients have been published previously.11 The trial 
was designed and overseen by a steering com-
mittee (see the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org) 
and was supported by unrestricted grants from 
Medtronic, St. Jude Medical, TrygFonden, and the 
Danish Heart Foundation; the funders had no 
influence on the design or conduct of the trial 
and were not involved in data collection or analy-
sis, in the writing of the manuscript, or in the 
decision to submit it for publication. The trial 
protocol, available at NEJM.org, was approved by 
the regional scientific ethics committee for the 
Capital Region of Denmark and the Danish Data 
Protection Agency. The trial was performed in 
accordance with the principles of the Declaration 
of Helsinki. The authors assume responsibility 
for the accuracy and completeness of the data 
and analyses, as well as for the fidelity of the 
trial and this report to the protocol.
Patients
Symptomatic patients (NYHA class II or III, or 
NYHA class IV if CRT was planned) with non-
ischemic systolic heart failure (left ventricular 
ejection fraction ≤35%) and an increased level 
(>200 pg per milliliter) of N-terminal pro–brain 
natriuretic peptide (NT-proBNP) were eligible for 
enrollment. The qualifying left ventricular ejec-
tion fraction and NT-proBNP level had to be mea-
sured after the doses of angiotensin-converting–
enzyme (ACE) inhibitors or angiotensin-receptor 
blockers and beta-blockers had been increased 
to target levels, which were the guideline-speci-
fied levels whenever possible. A nonischemic 
cause of heart failure was usually determined by 
coronary angiography, although a normal com-
puted tomographic (CT) angiogram or nuclear 
myocardial perfusion imaging study was accept-
able. Patients could be included even if they had 
one or two coronary arteries with stenoses, if 
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the extent of coronary artery disease was not 
considered to be sufficient to account for the re-
duced left ventricular systolic function. Patients 
with an existing conventional pacemaker or CRT 
pacemaker device could be included if the pa-
tients were willing to have the device changed or 
upgraded. Patients who had permanent atrial 
fibrillation with a resting heart rate higher than 
100 beats per minute or renal failure that was 
being treated with dialysis were excluded. A com-
plete list of the inclusion and exclusion criteria 
is provided in the Supplementary Appendix. All 
participants provided written informed consent.
Trial Procedures
Participants were randomly assigned in a 1:1 ratio 
to either the ICD group or the control group 
(usual clinical care). Randomization was per-
formed with the use of a Web-based system, in 
permuted blocks, with block sizes ranging from 
2 to 6 patients, and was stratified according to 
center and according to whether patients were 
scheduled to receive CRT. The decision to im-
plant a CRT device had to be made before ran-
domization. Implantation of an ICD (or a CRT 
pacemaker or CRT defibrillator) was planned to 
be performed no later than 4 weeks after random-
ization; all patients were seen at follow-up visits 
after 2 months and every 6 months thereafter 
until the end of the trial. Device programming 
and monitoring of the ICD followed routine clini-
cal practice (see the Supplementary Appendix).
Outcomes
The primary outcome was death from any cause. 
The secondary outcomes were sudden cardiac 
death, cardiovascular death, resuscitated cardiac 
arrest or sustained ventricular tachycardia, and 
change from baseline in quality of life (quality-
of-life outcomes are not discussed in this report). 
The outcome designated as “sudden cardiac death” 
probably included some instances of sudden 
vascular death, because, as we realized during 
the adjudication of outcomes, a clear distinction 
often could not be made between sudden cardiac 
death and sudden vascular death. However, be-
cause the term “sudden cardiac death” was used 
in the protocol and event definitions, we have re-
tained this term throughout. The safety outcome 
of device infection was prespecified; all other 
safety outcomes were based on adverse-event 
reporting. An end-point classification committee, 
the members of which were unaware of the treat-
ment assignments, used prespecified criteria to 
adjudicate all prespecified clinical outcomes (see 
the Supplementary Appendix for criteria).
Statistical Analysis
The study was designed to have 80% power to 
detect a 25% difference in total mortality be-
tween the treatment groups. At least 246 pri-
mary outcome events were required for the study 
to be conclusive, and we planned to include 1000 
patients. Because the event rate and enrollment 
rate were lower than expected, the steering com-
mittee decided to prolong enrollment until June 
30, 2014, or until 1200 patients were included 
(whichever came first) and to follow the last 
randomly assigned patient for at least 2 years. 
The baseline characteristics were compared be-
tween the treatment groups with the use of chi-
square and Wilcoxon tests. Outcomes were ana-
lyzed with the use of time-to-event methods. 
Kaplan–Meier plots were calculated for total 
mortality, and cumulative incidence curves were 
calculated for events with competing risk (sud-
den cardiac death and cardiovascular death). The 
analysis of the primary outcome was performed 
with a log-rank model stratified according to 
center and status with respect to planned implan-
tation of a CRT device. The proportional-hazard 
assumption was assessed with Schoenfeld residu-
als. Post hoc annual event rate ratios were de-
rived from a Poisson regression. Prespecified 
subgroup analyses of the primary outcome were 
performed for the variables shown in Table 1. 
All analyses were performed in the intention-to-
treat population. Two-sided P values of 0.05 or 
less were considered to indicate statistical sig-
nificance. Analyses were performed with SAS 
software, version 9.4 (SAS Institute), and R soft-
ware, version 3.3.1 (R Project for Statistical 
Computing).
R esult s
Characteristics of the Patients
From February 7, 2008, to June 30, 2014, a total 
of 1116 patients were enrolled at five centers; 
556 patients were randomly assigned to the ICD 
group, and 560 patients were assigned to the 
control group (Fig. 1). Overall, the two groups 
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Characteristic
ICD Group 
(N = 556)
Control Group 
(N = 560)
Median age (IQR) — yr 64 (56–72) 63 (56–70)
Female sex — no. (%) 151 (27) 156 (28)
Median blood pressure (IQR) — mm Hg
Systolic 123 (110–139) 124 (111–138)
Diastolic 74 (65–81) 74 (66–82)
Median body-mass index (IQR)† 26.8 (23.9–30.5) 26.8 (23.8–30.1)
Median NT-proBNP level (IQR) — pg/ml 1244 (616–2321) 1110 (547–2166)
Median QRS duration (IQR) — msec 146 (114–166) 145 (110–164)
Median left ventricular ejection fraction (IQR) — % 25 (20–30) 25 (20–30)
Median estimated GFR (IQR) — ml/min/1.73 m2 74 (58–91) 73 (58–92)
NYHA class — no. (%)
II 297 (53) 300 (54)
III 252 (45) 253 (45)
IV 7 (1) 7 (1)
Median duration of heart failure (IQR) — mo 20 (8–72) 18 (8–60)
Coexisting conditions — no. (%)
Hypertension 181 (33) 167 (30)
Diabetes 99 (18) 112 (20)
Permanent atrial fibrillation 135 (24) 113 (20)
Means of exclusion of ischemic cause of heart failure — no. (%)
Nuclear study 5 (1) 8 (1)
CT angiogram 18 (3) 11 (2)
Catheterization 533 (96) 541 (97)
Cause of heart failure — no. (%)
Idiopathic 424 (76) 425 (76)
Valvular 20 (4) 21 (4)
Hypertension 62 (11) 55 (10)
Other 50 (9) 59 (11)
Medications — no. (%)
ACE inhibitor or ARB 533 (96) 544 (97)
Beta-blocker 509 (92) 517 (92)
Mineralocorticoid-receptor antagonist 326 (59) 320 (57)
Amiodarone 34 (6) 32 (6)
CRT — no. (%) 322 (58) 323 (58)
Preexisting pacemaker or CRT pacemaker — no. (%) 56 (10) 46 (8)
*  There were no significant differences (P<0.05) between the study groups. ACE denotes angiotensin-converting enzyme, 
ARB angiotensin-receptor blocker, CRT cardiac resynchronization therapy, CT computed tomography, GFR glomerular 
filtration rate, ICD implantable cardioverter–defibrillator, IQR interquartile range, NT-proBNP N-terminal pro–brain 
 natriuretic peptide, and NYHA New York Heart Association.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Characteristics of the Patients at Baseline.*
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were balanced with respect to baseline charac-
teristics (Table 1). In both groups, 58% of pa-
tients received CRT. The majority of patients re-
ceived target doses of heart failure medication in 
accordance with the guidelines that were avail-
able at the time of the trial (Table S1 in the Sup-
plementary Appendix), and among the patients 
with wide left bundle-branch block (QRS dura-
tion, ≥150 msec), 93% received CRT (see Table 
S2 in the Supplementary Appendix for baseline 
demographic characteristics according to CRT 
status and treatment group).
Device Implantation
In the ICD group, 4 patients required two at-
tempts at implantation, and 14 patients did not 
receive an ICD (1 patient died before implanta-
tion, implantation was unsuccessful in 2 patients, 
and 11 patients withdrew consent before im-
plantation). The median time from randomiza-
tion to implantation was 31 days (interquartile 
range, 19 to 43). A total of 27 patients in the 
control group received an ICD (24 because of an 
arrhythmic event and 3 at the request of their 
physician). During the trial, 85 patients (15.3%) 
Figure 1. Enrollment and Randomization of Patients.
Details regarding device implantation and upgrades in the control group are provided in the Supplementary Appendix. CRT denotes 
cardiac resynchronization therapy, and ICD implantable cardioverter–defibrillator.
1116 Patients were eligible
for randomization
8 Did not undergo 
ICD implantation
1 Died before
implantation
1 Had unsuccess-
ful implantation
6 Withdrew consent
11 Had ICD extracted
or deactivated
6 Did not undergo 
ICD implantation
1 Had unsuccess-
ful implantation
5 Withdrew consent
19 Had ICD extracted
or deactivated
306 Remained without
       ICD during trial
17 Underwent ICD
implantation 
during trial
15 Had arrhythmia
2 Underwent
implantation at
physician request
227 Remained without
       ICD during trial
10 Underwent ICD
implantation
during trial
9 Had arrhythmia
1 Underwent
implantation at 
physician request
303 Had ICD throughout
trial
209 Had ICD throughout
trial
645 Underwent randomization 471 Underwent randomization
471 Did not have indication
for CRT
626 Had indication
for CRT
19 Had preexisting CRT
234 Were assigned
to ICD group
237 Were assigned
to control group
322 Were assigned
to ICD group
323 Were assigned
to control group
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in the ICD group had the battery in their ICD 
replaced, and 30 patients had the device re-
moved or permanently deactivated because of an 
infection or by request (Fig. 1).
Follow-up and Outcomes
Follow-up data for all outcomes were available 
through June 30, 2016. The median follow-up 
period was 67.6 months (interquartile range, 49 
to 85), and no patients were lost to follow-up for 
the primary outcome.
The primary outcome, death from any cause, 
occurred in 120 patients (21.6%) in the ICD group 
(4.4 events per 100 person-years) and in 131 
patients (23.4%) in the control group (5.0 events 
per 100 person-years) (Fig. 2A and Table 2). The 
hazard ratio for death from any cause in the ICD 
group, as compared with the control group, was 
0.87 (95% confidence interval [CI] 0.68 to 1.12; 
P = 0.28). The test for the proportional-hazard as-
sumption with Schoenfeld residuals gave a P value 
of 0.054. Annual event rate ratios from post hoc 
analyses are provided in Table S3 in the Supple-
mentary Appendix. Cardiovascular death occurred 
in 77 patients (13.8%) in the ICD group and in 
95 patients (17.0%) in the control group (hazard 
ratio, 0.77; 95% CI, 0.57 to 1.05; P = 0.10) (Ta-
ble 2 and Fig. 2B). Sudden cardiac death occurred 
in 24 patients (4.3%) in the ICD group and in 46 
patients (8.2%) in the control group (hazard 
ratio, 0.50; 95% CI, 0.31 to 0.82; P = 0.005) (Ta-
ble 2 and Fig. 2C). The clinical outcome of resus-
citated cardiac arrest or sustained ventricular 
tachycardia occurred with similar frequency in 
the two groups (Table 2); termination of ven-
tricular tachycardia by antitachycardia pacing 
occurred in 97 patients (17.4%) in the ICD group, 
and appropriate shock for ventricular fibrillation 
or rapid ventricular tachycardia was given for 64 
patients (11.5%) in the ICD group.
The results of subgroup analyses are shown in 
Fig. 3. The results were similar across all subgroups 
with the exception of age, for which there was 
a significant treatment-by-subgroup interaction 
(P = 0.009 for the interaction) (Fig. 3, and Fig. S1 
in the Supplementary Appendix). In the subgroup 
of patients who were younger than 68 years of 
age, the rate of death from any cause was signifi-
cantly lower in the ICD group than in the control 
group (hazard ratio, 0.64; 95% CI, 0.45 to 0.90; 
P = 0.01). The effect of ICD implantation was in-
dependent of CRT status (P = 0.73 for the inter-
action) (Fig. S2 in the Supplementary Appendix).
Safety
Device infections occurred in 27 patients (4.9%) 
in the ICD group and in 20 patients (3.6%) in the 
control group (P = 0.29) (Table 2). Among patients 
Figure 2. Time-to-Event Curves for Death from Any Cause, Cardiovascular 
Death, and Sudden Cardiac Death.
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who were not receiving CRT, the risk of device 
infection was higher in the ICD group than it 
was in the control group (12 of 234 patients 
[5.1%] vs. 2 of 237 patients [0.8%]; hazard ratio, 
6.35; 95% CI, 1.38 to 58.87; P = 0.006). Inappro-
priate shocks occurred in 33 patients (5.9%) in 
the ICD group (Table 2); 28 of the shocks were 
due to atrial fibrillation, 4 were due to oversens-
ing, and 1 was due to supraventricular arrhyth-
mia other than atrial fibrillaton. One patient had 
the ICD deactivated because of several shocks. 
Other complications during implantation were 
uncommon and occurred in both groups, because 
many of the control patients received a CRT de-
vice (Table 2).
Discussion
We found that implantation of an ICD in pa-
tients who had heart failure that was not caused 
by ischemic heart disease did not provide an 
overall survival benefit, although the risk of sud-
den cardiac death was halved with an ICD. There 
was an important interaction with age that sug-
gested that younger patients may have a survival 
benefit in association with ICD implantation. 
The results were independent of whether a pa-
tient received a CRT device.
All time-to-event curves appeared to diverge 
during the initial 5 years of the trial and then to 
converge (Fig. 2). Post hoc analysis of annual 
event rate ratios (Supplementary Appendix) sup-
ports this interpretation. This observation lends 
support to the rationale for long-term studies, 
since the most common causes of death may 
change over time in patients with heart failure. 
In previous trials that showed a benefit from ICD 
implantation in patients with ischemic heart dis-
ease, the number needed to treat in order to save 
one life was as low as 6 over an 8-year period.3,12,13 
Outcome
ICD Group† 
(N = 556)
Control Group† 
(N = 560) Hazard Ratio (95% CI) P Value
no. of patients/total no. (%)
Death from any cause 120 (21.6) 131 (23.4) 0.87 (0.68–1.12) 0.28
Cardiovascular death 77 (13.8) 95 (17.0) 0.77 (0.57–1.05) 0.10
Sudden cardiac death 24 (4.3) 46 (8.2) 0.50 (0.31–0.82) 0.005
Other cardiovascular death 53 (9.5) 49 (8.8) 1.03 (0.70–1.52) 0.89
Noncardiovascular death 43 (7.7) 36 (6.4) 1.12 (0.72–1.76) 0.60
Resuscitated cardiac arrest or sustained VT 26 (4.7) 25 (4.5) 1.03 (0.59–1.79) 0.91
Cardiac arrest 11 (2.0) 14 (2.5) 0.79 (0.36–1.75) 0.56
Sustained VT requiring medical intervention  
or electrical conversion
16 (2.9) 14 (2.5) 1.12 (0.54–2.30) 0.76
Odds Ratio (95% CI)
Device infection 27 (4.9) 20 (3.6) 1.38 (0.73–2.63) 0.29
CRT‡ 15/322 (4.7) 18/323 (5.6) 0.83 (0.38–1.78) 0.60
No CRT‡ 12/234 (5.1) 2/237 (0.8) 6.35 (1.38–58.87) 0.006
Serious device infection§ 15 (2.7) 13 (2.3) 1.17 (0.51–2.69) 0.69
CRT‡ 9/322 (2.8) 11/323 (3.4) 0.82 (0.29–2.20) 0.65
No CRT‡ 6/234 (2.6) 2/237 (0.8) 3.09 (0.54–31.56) 0.24
Bleeding requiring intervention 1 (0.2) 0 — —
Pneumothorax 11 (2.0) 6 (1.1) 1.86 (0.68–5.08) 0.22
Inappropriate shocks 33 (5.9) 0 — —
*  VT denotes ventricular tachycardia.
†  Total numbers are included when they differ from those in the overall study group. A total of 348 patients in the control group received a 
device (CRT pacemaker, ICD, CRT defibrillator, or bradycardia pacemaker) after randomization and were susceptible to device complications. 
Details regarding device implantation and upgrades in the control group are provided in the Supplementary Appendix.
‡  Percentages were calculated with the numbers of patients scheduled for CRT and the numbers of patients not scheduled for CRT as the de-
nominators.
§  A serious device infection was defined as infection requiring lead extraction or lifelong antibiotic treatment or causing death (see the Supple-
mentary Appendix).
Table 2. Outcomes and Adverse Events.*
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There may be several explanations for the differ-
ence between these results and our findings. 
Patients with nonischemic heart failure may be 
less prone to death from arrhythmia than pa-
tients with ischemic heart failure, but better 
medical treatment and CRT also may have re-
duced the risk of death from arrhythmia for all 
patients with heart failure. Our event rate was 
lower than that observed in older studies, which 
reflects the fact that our study population con-
Figure 3. Rate of Death from Any Cause (Primary Outcome) in Prespecified Subgroups.
GFR denotes glomerular filtration rate, LV left ventricular, NT-proBNP N-terminal pro–brain natriuretic peptide, and NYHA New York 
Heart Association.
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<59 yr
≥59 to <68 yr
≥68 yr
Sex
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Male
NT-proBNP
<1177 pg/ml
≥1177 pg/ml
LV ejection fraction
<25%
≥25%
Estimated GFR
<73 ml/min/1.73 m2
≥73 ml/min/1.73 m2
NYHA functional class
II
III–IV
Heart failure duration
<18 mo
≥18 mo
Hypertension
No
Yes
Diabetes
No
Yes
Permanent atrial fibrillation
No
Yes
Cause of heart failure
Idiopathic
Valvular
Hypertension
Other
Preexisting pacemaker 
No
Yes
CRT
No
Yes
Overall
Hazard Ratio (95% CI)ICD Group Control GroupSubgroup
0.25
P Value for
Interaction
17/167
36/173
67/216
22/151
98/405
32/266
57/292
70/264
50/292
75/272
45/283
52/297
68/259
31/254
89/301
78/375
42/181
87/457
33/99  
83/421
37/135
90/424
4/20
13/62  
13/50  
108/500  
12/56  
58/234
62/322
34/181
50/202
47/177
23/156
108/404  
74/268
88/290
65/242
66/318
80/278
50/280
54/300
77/260
36/277
95/283
87/392
44/167
95/448
36/112
91/447
40/113
100/425  
5/21
12/55  
14/59  
120/514  
11/46  
65/237
66/323
0.009
0.66
0.06
0.69
0.86
0.71
0.73
0.63
0.60
0.30
0.80
0.71
0.73
P Value 
0.02
0.19
0.38
0.92
0.24
0.02
0.96
0.42
0.21
0.42
0.33
0.68
0.21
0.61
0.17
0.48
0.27
0.26
0.74
0.58
0.24
0.37
0.50
0.39
0.96
0.34
0.79
0.31
0.59
0.28
no. of events/total no.
0.51 (0.29−0.92)
0.75 (0.48−1.16)
1.19 (0.81−1.73)
1.03 (0.57−1.87)
0.85 (0.64−1.12)
0.59 (0.38−0.91)
0.99 (0.73−1.36)
0.87 (0.62−1.22)
0.79 (0.54−1.14)
0.88 (0.64−1.21)
0.82 (0.55−1.23)
0.92 (0.63−1.35)
0.81 (0.58−1.13)
0.88 (0.54−1.43)
0.81 (0.61−1.09)
0.90 (0.66−1.22)
0.79 (0.51−1.21)
0.85 (0.63−1.31)
0.92 (0.57−1.50)
0.92 (0.68−1.24)
0.76 (0.48−1.20)
0.88 (0.66−1.17)
0.59 (0.13−2.71)
0.68 (0.29−1.63)
1.02 (0.47−2.20)
0.88 (0.68−1.14)
0.88 (0.36−2.20)
0.83 (0.58−1.19)
0.91 (0.64−1.29)
0.87 (0.68−1.12)
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sisted predominantly of outpatients who were in 
stable condition and who were treated medically 
in accordance with the guidelines, with almost 
every patient receiving beta-blockers and inhibi-
tors of the renin–angiotensin system and 60% of 
the patients receiving mineralocorticoid-receptor 
antagonists.
We did not find a difference in the relative 
effect of an ICD between patients who received 
CRT and patients who did not. However, data on 
causes of death from observational studies in-
volving patients receiving CRT suggest that an 
ICD may not be beneficial in the majority of 
these patients.14 In the COMPANION trial, the 
overall difference in mortality between the CRT 
defibrillator group and the CRT pacemaker group 
was not tested statistically.10 In later analyses of 
the data by independent authors, the crude P value 
based on overall mortality in the CRT pacemaker 
group versus the CRT defibrillator group was 
calculated as 0.12.15,16 At present, it is therefore 
unclear whether patients who are eligible for 
CRT should routinely receive an ICD, and a study 
in which patients are randomly assigned to re-
ceive a CRT pacemaker or a CRT defibrillator 
would be of potential clinical importance.16
In the current study, 31% of deaths were at-
tributed to noncardiovascular causes. This is not 
surprising in an elderly population, but it high-
lights the importance of selecting patients for 
ICD implantation carefully. The rate of death 
among the patients we included in our trial was 
relatively low, and patients at higher risk may be 
more likely to benefit from ICD implantation. 
However, the subgroup data that suggest a lower 
likelihood of benefit in older patients might be 
used as an argument for not implanting ICDs in 
frail patients. Also, the benefit of ICD implanta-
tion with respect to sudden cardiac death that was 
seen in our trial is convincing, and patients who 
are not expected to die from other causes may 
be good candidates for ICD implantation. Long-
term data from the Multicenter Automatic Defi-
brillator Implantation Trial (MADIT) II indicate 
that clinical risk scores may make it possible to 
identify the patients with ischemic heart disease 
who will benefit most from ICD implantation.12 
Such a method for identifying patients with non-
ischemic heart failure who are at high risk for 
death from arrhythmia would be very useful.
The side effects associated with device im-
plantation in our trial were not trivial. Device-
related infections were not infrequent, but we 
did have a high proportion of patients in both 
groups who were receiving CRT (which requires 
implantation of an additional lead in the coro-
nary sinus). In addition, 10% of our patients al-
ready had a pacemaker and were randomly as-
signed either to receive or not to receive an ICD 
upgrade; this is a patient group that has not been 
included in most of the previous trials. In a re-
cent study, major device-related complications 
occurred within the first 6 months after implan-
tation in approximately 6% of patients who re-
ceived an ICD and 11% of patients who received 
a CRT defibrillator.17 Rates of inappropriate shocks 
or inappropriate antitachycardia pacing have de-
creased in recent years with the use of less ag-
gressive ICD settings, but even with these modi-
fications, 6% of patients have inappropriate 
shocks within 2.5 years after implantation of a 
dual-chamber ICD.13 These figures are similar to 
the 5.9% of patients who received inappropriate 
shocks in our trial.
The DANISH trial adds to the available body 
of data to consider in formulating the indica-
tions for ICD implantation in patients with non-
ischemic systolic heart failure. In the current 
American Heart Association guidelines, ICD im-
plantation for primary prevention of sudden car-
diac death in patients with symptomatic systolic 
heart failure is a class 1A recommendation, with 
no differentiation between patients with ische mic 
and nonischemic causes.1 In the European guide-
lines, ICD implantation is a class 1B recommen-
dation for patients with nonischemic heart fail-
ure, as opposed to a class 1A recommendation 
for patients with ischemic heart failure.2 The 
American Heart Association guidelines refer sole-
ly to the SCD-HeFT trial for their recommenda-
tions regarding ICD implantation in patients with 
nonischemic causes of heart failure, whereas the 
European guidelines also refer to the Defibrilla-
tors in Non-Ischemic Cardiomyopathy Treatment 
Evaluation (DEFINITE) trial. However, SCD-HeFT 
enrolled patients between 1997 and 2001, and 
only 69% of enrolled patients received beta-
blockers at baseline, 20% of patients received a 
mineralocorticoid-receptor antagonist, and no 
patients received concomitant CRT.6 In addition, 
the designation of ischemic or nonischemic 
causes in the SCD-HeFT trial was based primar-
ily on patient history, with results from coronary 
angiography used to designate the cause only if 
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such results were available. The DEFINITE trial, 
which enrolled patients between 1998 and 2002, 
included a larger proportion of patients who re-
ceived beta-blockers (85%) but, again, no patients 
who received CRT.9
In conclusion, in our trial, prophylactic ICD 
implantation in patients with symptomatic sys-
tolic heart failure that was not caused by coro-
nary artery disease was not found to reduce long-
term mortality.
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